Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.
Journal: JAMA neurology
Published: February 16, 2026
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.
Journal: Frontiers in immunology
Published: December 19, 2025
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
Journal: Neurology and therapy
Published: December 16, 2025
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.
Journal: Advances in therapy
Published: October 23, 2025
The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants.
Journal: Contemporary clinical trials
Published: May 12, 2025
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.
Journal: Neurology and therapy
Published: March 19, 2025
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.
Journal: Advances in therapy
Published: August 23, 2024
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.
Journal: Annals of clinical and translational neurology
Published: August 01, 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.
Journal: Frontiers in neurology
Published: July 30, 2024
Use of Calcitonin Gene-Related Peptide Monoclonal Antibodies for the Treatment of Migraines in Individuals With Multiple Sclerosis.
Journal: International journal of MS care
Published: May 20, 2024
Time-Dependent Deep Learning Prediction of Multiple Sclerosis Disability.
Journal: Journal of imaging informatics in medicine
Published: December 06, 2023
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 11, 2023
Last Updated: 09/26/2026